Biocytogen Secures U.S. Patent for Innovative RenLite Platform, Boosting Global Antibody Research

Biocytogen Pharmaceuticals has been granted a U.S. patent for its RenLite® fully human common light chain mouse platform. This innovation, developed using Biocytogen's proprietary technology, simplifies the creation of diverse human antibodies. The RenLite platform, alongside RenMice® series, has received global industry recognition and fosters rapid antibody development.

Biocytogen Pharmaceuticals has reached a significant milestone with the U.S. Patent and Trademark Office granting a patent for its RenLite® fully human common light chain mouse platform. This patent acknowledges the company's innovative prowess in the biotechnology arena.

Developed using Biocytogen's pioneering Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, RenLite mice facilitate the creation of highly diverse fully human antibodies. By enabling the in situ replacement of human antibody genes, RenLite effectively minimizes the complexity associated with bispecific antibody production.

Alongside RenLite, Biocytogen's RenMice® series continues to cater to the diverse research and development needs of pharmaceutical companies worldwide, marking Biocytogen as a leader in antibody technology innovation.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)